Viking Flexes Its Muscles Ahead Of Partnering Talks
Executive Summary
The mid-stage company is approaching Phase II data read outs for two lead assets. It is looking to partner with larger pharmas, but is also pursuing orphan indications that it could develop independently.
You may also be interested in...
Viking’s Liver Fat Reduction Data Portend A New Competitor In NASH
In a Phase II study, Viking’s VK2809, with the same mechanism as Madrigal’s MGL-3196, shows significant liver fat reduction in NAFLD patients, along with reduction in LDL cholesterol.
Viking's Post-Hip Fracture Drug Succeeds In Phase II, But Pivotal Endpoints Unclear
The company's oral non-steroidal SARM could be the first approved drug to help patients maintain muscle after hip fracture surgery, but will FDA seek pivotal data on muscle mass or on functional measures?
Intercept Increases Chance Of Success In NASH Without Significant Delay
Ocaliva could now qualify for accelerated approval in NASH by meeting either of two Phase III co-primary endpoints, whereas the trial initially was designed for success on both measures.